MDN-6, a Possible Therapeutic Candidate for Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis

Background: The rise of antibiotic-resistant Mycobacterium tuberculosis strains has accelerated the hunt for novel drugs (TB). Objectives: This study identified a compound with strong anti-TB efficacy against several resistant M. from chemical library naphthoquinone derivatives. Methods: was designated as MDN-6 (methyl-1,4-bis(2-(diethylamino)ethoxy)-2-naphthoate). Results: It significantly inhibited all tested strains, including 24 clinically isolated strains. minimum inhibitory concentrations were between 0.02 and 25 g/mL. also had partially synergistic activity extensively drug-resistant when coupled rifampicin streptomycin. Additionally, demonstrated superior post-antibiotic effect over isoniazid exhibited comparable marinum kansasii. Besides antimicrobial effect, 50% lethal dosage (LD50) 279.1 mg/kg in female BALB/c mice. Conclusions: is promising therapeutic candidate tuberculosis. However, further investigation necessary to elucidate action mechanism assess drug’s vivo potential.